JC virus in the Irish population: Significant increase of genotype 2 in immunocompromised individuals
详细信息 查看全文
- 作者：Kirsten Schaffer (1) (2)
Noreen Sheehy (1)
Suzie Coughlan (2)
Colm Bergin (3)
William W. Hall (1) (2) - 关键词：genotypes ; immunodeficiency ; JC virus ; VP1 gene
- 刊名：Journal of NeuroVirology
- 出版年：2006
- 出版时间：January 2006
- 年：2006
- 卷：12
- 期：1
- 页码：39-46
- 全文大小：291KB
- 参考文献：1. Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, Frias C, Perez-Trallero E, Ryschkewitsch CF, Stoner GL (2001). Genotypes of JC virus in East, Central and Southwest Europe. / J Gen Virol 82: 1221鈥?331.
2. Agostini HT, Ryschkewitsch CF, Mory R, Singer EJ, Stoner GL (1997). JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: increased frequency of JCV type 2 in PML. / J Infect Dis 176: 1鈥? CrossRef
3. Agostini HT, Ryschkewitsch CF, Singer EJ, Baumhefner RW, Stoner GL (1998a). JC virus type 2B is found more frequently in brain tissue of progressive multifocal leukoencephalopathy patients than in urine from controls. / J Hum Virol 3: 200鈥?06.
4. Agostini HT, Ryschkewitsch CF, Stoner GJ (1998b). JC virus type 1 has multiple subtypes: three new complete genomes. / J Gen Virol 79: 801鈥?05.
5. Agostini HT, Shishido-Hara Y, Baumhefner RW, Singer EJ, Ryschkewitsch CF, Stoner GL (1998c). JC virus type 2: definition of subtypes based on DNA sequence analysis of ten complete genomes. / J Gen Virol 79: 1143鈥?151.
6. Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Khoo SH (2004). Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. / J Clin Virol 29: 224鈥?29. CrossRef
7. Berger JR (2003). Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. / J NeuroVirol 9(Suppl l): 38鈥?1.
8. Centers for Disease Control and Prevention (CDC) (2004). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002鈥?003. / MMWR Morb Mortal Wkly Rep 53: 683鈥?86.
9. Daniel DC, Wortman MJ, Schiller RJ, Liu H, Gan L, Mellen JS, Chang C-F, Gallia GL, Rappaport J, Khalili K, Johnson EM (2001). Coordinate effects of human immunodeficiency virus type 1 protein Tat and cellular protein Pur伪 on DNA replication initiated at the JC virus origin. / J Gen Virol 82: 1543鈥?553.
10. Dubois V, Moret H, Lafon M-E, Brodard V, Icart J, Ruffault A, Guist鈥檋au O, Buffet-Janvresse C, Abbed K, Dussaix E, Ingrand D (2001). JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. / J Infect Dis 183: 213鈥?17. CrossRef
11. Ferrante P, Mediati M, Caldarelli-Stefano R, Losciale L, Manusco R, Cagni AE, Maserati R (2001). Increased frequency of JC virus type 2 and of dual infection with JC virus type 1 and 2 in Italian progressive multifocal leukoencephalopathy patients. / J NeuroVirol 7: 35鈥?2. CrossRef
12. Frisque RJ, Bream GL, Cannella MT (1984). Human polyomavirus JC virus genome. / J Virol 51: 458鈥?69.
13. Hatwell JN, Sharp PM (2000). Evolution of human polyomavirus JC. / J Gen Virol 81: 1191鈥?200.
14. Kitamura T, Kunitake T, Quo J, Tominaga T, Kawabe K, Yogo Y (1994). Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. / J Clin Microbiol 32: 2359鈥?363.
15. Kleinschmidt-DeMasters BK, Tyler KL (2005). Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. / N Engl J Med 353: 369鈥?74. CrossRef
16. Krachmarov CP, Chepenik LG, Barr-Vagell S, Khalili K, Johnson EM (1996). Activation of the JC virus Tatresponsive transcriptional control element by association of the Tat protein of human immunodeficiency virus 1 with cellular protein Pur伪. / Proc Natl Acad Sci U S A 93: 14112鈥?4117. CrossRef
17. Lednicky JA, Vilchez RA, Keitel WA, Visnegarwala F, White ZS, Kozinetz CA, Lewis DE, Butel JS (2003). Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. / AIDS 17: 801鈥?07. CrossRef
18. Major EO (2001). Human polyomavirus. In: / Virology. Fields BN, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE, Knipe DM (eds). Philadelphia: Lippincott Williams, pp 2175鈥?196.
19. Pagani E, Delbue S, Manusco R, Borghi E, Tarantini L, Ferrante P (2003). Molecular analysis of JC virus genotypes circulating among the Italian healthy population. / J NeuroVirol 9: 559鈥?66.
20. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J (2003). Seroepidemiology of the human polyomaviruses. / J Gen Virol 84: 1499鈥?504. CrossRef
21. Sundsfjord A, Flaegstad T, Flo R, Spein AR, Pedersen M, Permin H, Julsrud J, Traavik T (1994). BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions. / J Infect Dis 169: 485鈥?90. CrossRef
22. Tsai R-T, Wang M, Ou W-C, Lee Y-L, Li S-Y, Fung C-Y, Huang Y-L, Tzeng T-Y, Chen Y, Chang D (1997). Incidence of JC viruria is higher than that of BK viruria in Taiwan. / J Med Virol 52: 253鈥?57. CrossRef
23. Van Assche G, Van Raust M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005). Progressive multifocal leukoencephalopathy after natalizumab therapy for Chron鈥檚 disease. / N Engl J Med 353(4): 362鈥?68. CrossRef
24. Venter M, Smit SB, Leman P, Swanepoel R (2004). Phylogenetic evidence of widespread distribution of genotype 3 JC virus in Africa and identification of a type 7 isolate in an African AIDS patient. / J Gen Virol 85: 2215鈥?219. CrossRef
25. Wang M, Tsai R-T, Ou W-C, Lin C-K, Tsay GJ, Chang H, Chang D (2000). Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease. / J Med Virol 62: 505鈥?10. CrossRef
26. Yanagihara R, Nerurkar VR, Scheirich I, Agostini HT, Mgone CS, Cui X, Jobes DV, Cubitt CL, Ryschkewitsch CF, Hroly DB, Friedlaender JS, Stoner GL (2002). JC virus genotypes in the western Pacific suggest Asian mainland relationships and virus association with early population movements. / Hum Biol 74: 473鈥?88. CrossRef
27. Zheng H-Y, Takasaka T, Noda K, Kanazawa A, Mori H, Kabuki T, Joh K, Oh-ishi T, Ikegaya H, Nagashima K, Hall WW, Kitamura T, Yogo Y (2005). New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. / J Gen Virol 86: 2035鈥?045. CrossRef - 作者单位：Kirsten Schaffer (1) (2)
Noreen Sheehy (1)
Suzie Coughlan (2)
Colm Bergin (3)
William W. Hall (1) (2)
1. Department of Medical Microbiology, Centre for Research in Infectious Diseases, University College Dublin, Dublin, Ireland
2. National Virus Reference Laboratory, University College Dublin, Dublin, Ireland
3. Department of Infectious Diseases, St James鈥檚 Hospital, Dublin, Ireland - ISSN：1538-2443
文摘
The human polyomavirus JC virus (JCV) is ubiquitous and can be shed in the urine of more than 40% of the healthy population. Amplification and sequencing of JCV from urine has allowed a distinctive map of the distribution of JCV genotypes worldwide. To define the frequency of JCV urinary excretion and genotype distribution in Ireland, urines from 121 healthy individuals and from 94 immunocompromised individuals (human immunodeficiency virus [HIV]-positive patients and rheumatoid arthritis patients) were collected. JCV DNA was detected by polymerase-chain reaction (PCR) with subsequent nucleotide sequencing of a fragment of the major capsid protein (VP1). JCV was detected in 20.7% of healthy individuals and was found significantly more often in the urine of HIV-positive patients (54.2%; P < .001) and rheumatoid arthritis patients (54.4%; P < .001). In healthy Irish individuals genotype 1 was the predominant genotype in 62.5%, followed by genotype 4 in 16.7% and genotype 2 in 12.5%. In contrast, genotype 2 was significantly more often isolated from the urine of both HIV-positive patients (60%) and rheumatoid arthritis patients (54.4%; P < .01). The pattern of genotype distribution among healthy Irish individuals is in agreement with data reported from other European countries, whereas the overall level of JCV urinary excretion is lower. Previous studies have found genotype 2 significantly more often in cerebrospinal (CSF) samples of patients with progressive multifocal leukoencephalopathy (PML). Here the authors report an increased frequency of genotype 2 in urine samples of immunocompromised non-PML patients. This finding further underlines the hypothesis that there could be biologic differences between JCV genotypes.